Legal status · United Kingdom
Is Pegcetacoplan legal in the United Kingdom?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
Yes. Pegcetacoplan is an approved medicine in the United Kingdom, classified as "Licensed for the blood indication only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Pegcetacoplan in the United Kingdom at a glance
| Classification | Licensed for the blood indication only |
|---|---|
| Note | The systemic product is authorised in Europe for paroxysmal nocturnal haemoglobinuria. The intravitreal geographic atrophy product was refused: the European Medicines Agency committee adopted a negative opinion in June 2024 and confirmed it on re-examination in September 2024, on the grounds that slowing lesion growth did not produce a clinically meaningful benefit for patients. |
| MHRA approval status | Approved by MHRA for its labeled use |
| Human studies cited | 4 of 4 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Pegcetacoplan profile, checked against Medicines and Healthcare products Regulatory Agency (MHRA) listings at the reviewed date.
What this means
- 01
MHRA has approved Pegcetacoplan for at least one labeled indication, so a pharmaceutical-grade product exists in the United Kingdom and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Pegcetacoplan is
The same molecule holds two unrelated approvals: subcutaneous Empaveli for paroxysmal nocturnal haemoglobinuria, where it beat eculizumab by 3.84 g/dL of haemoglobin at 16 weeks, and intravitreal Syfovre for geographic atrophy, where it slowed lesion growth by 16 to 22 percent and showed no difference on any visual function endpoint at 24 months. European regulators refused the eye indication on exactly that point.
Pegcetacoplan is a symmetrical construct of two identical 13-residue cyclic peptides joined by a 40 kDa linear polyethylene glycol linker. Most of its mass is the PEG.
Mechanism: Binding to complement C3 and its activation fragment C3b, preventing cleavage of C3 and therefore blocking the common step shared by the classical, lectin and alternative complement pathways. Because C3 is upstream of C5, inhibition removes both the terminal membrane attack complex that lyses red cells in the circulation and the C3b opsonisation that tags them for removal by the liver and spleen.
Regulatory history: FDA-approved twice. Empaveli, NDA 215014, approved 14 May 2021, subcutaneous infusion, for paroxysmal nocturnal haemoglobinuria in adults and now also for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis from age 12. Syfovre, NDA 217171, approved 17 February 2023, intravitreal injection, for geographic atrophy secondary to age-related macular degeneration. The European Medicines Agency refused the geographic atrophy indication in 2024.
How MHRA treats this kind of product
Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.
The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Pegcetacoplan at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Pegcetacoplan in other countries
Frequently asked questions
Is Pegcetacoplan legal in the United Kingdom?
Yes. Pegcetacoplan is an approved medicine in the United Kingdom, classified as "Licensed for the blood indication only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: The systemic product is authorised in Europe for paroxysmal nocturnal haemoglobinuria. The intravitreal geographic atrophy product was refused: the European Medicines Agency committee adopted a negative opinion in June 2024 and confirmed it on re-examination in September 2024, on the grounds that slowing lesion growth did not produce a clinically meaningful benefit for patients.
Can I buy Pegcetacoplan in the United Kingdom?
Only with a prescription. Pegcetacoplan is classified as "Licensed for the blood indication only" in the United Kingdom, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection. Note: The systemic product is authorised in Europe for paroxysmal nocturnal haemoglobinuria. The intravitreal geographic atrophy product was refused: the European Medicines Agency committee adopted a negative opinion in June 2024 and confirmed it on re-examination in September 2024, on the grounds that slowing lesion growth did not produce a clinically meaningful benefit for patients.
Is Pegcetacoplan MHRA approved?
Yes, for its labeled indication. In the United Kingdom Pegcetacoplan is classified as "Licensed for the blood indication only". For comparison, the US FDA status is: FDA-approved twice. Empaveli, NDA 215014, approved 14 May 2021, subcutaneous infusion, for paroxysmal nocturnal haemoglobinuria in adults and now also for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis from age 12. Syfovre, NDA 217171, approved 17 February 2023, intravitreal injection, for geographic atrophy secondary to age-related macular degeneration. The European Medicines Agency refused the geographic atrophy indication in 2024.. On the evidence, 4 human studies are cited on its profile.
Related compounds in the United Kingdom
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Pegcetacoplan live on its compound profile.
Pegcetacoplan profileThis page is general information about the regulatory status of Pegcetacoplan in the United Kingdom, current as of Sep 2026. It is not legal advice, and classifications change; check Medicines and Healthcare products Regulatory Agency directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.